| Name | Title | Contact Details |
|---|
QuietAgent finds you jobs that are right for you. Get a killer resume, specify what you want, and let QuietAgent do the work.
From planning and documentation to billing and beyond, Radformation`s user-friendly, FDA-cleared tools seamlessly integrate into your workflow to increase quality and efficiency in all stages of the treatment planning process. ClearCheck, our automated plan check and documentation software, ensures the highest quality treatment plans and helps clinics save time with 80+ plan checks and instant documentation. ClearCalc, our independent calculation software, efficiently validates plan accuracy, providing instant dose validation of photon, brachytherapy, and electron plans. EZFluence automatically generates high-quality 3D plans in just one click—for any beam arrangement and any treatment site from head to toe. AutoContour, our fast and accurate automated AI contouring software, automatically segments 50 of the most commonly delineated clinical structures in seconds. ChartCheck, our treatment evaluation software, actively monitors patient data in real-time to ensure safety for ongoing treatments. QuickCode billing QA software instantly evaluates charges, automatically catching missed or incorrect codes and ensuring appropriate compensation. Save time and resources while increasing quality and safety with Radformation.
Proactive intelligence platform that empowers real estate development via Northspyres commercial real estate software
CENSURA is a Mason, OH-based company in the Software and Internet sector.
Immunome is a biotechnology company with a growing pipeline of cancer immunotherapies fueled by the human immune system. Our unique and powerful immunotherapy discovery engine leverages “most highly educated” immune systems from patients who have already learned how to fight off their disease. This proprietary technology platform enables the simultaneous discovery of novel antigens and the patient-derived, native antibodies that target those antigens. We then employ a battery of high-content screening technologies to identify specific and high-affinity antibodies that offer significant therapeutic potential to change the way we treat cancer.